Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 12
2016 7
2017 8
2018 8
2019 7
2020 10
2021 6
2022 8
2023 11
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Pregnancy-Associated Breast Cancer: A Multidisciplinary Approach.
Paris I, Di Giorgio D, Carbognin L, Corrado G, Garganese G, Franceschini G, Sanchez AM, De Vincenzo RP, Accetta C, Terribile DA, Magno S, Di Leone A, Bove S, Masetti R, Scambia G. Paris I, et al. Among authors: carbognin l. Clin Breast Cancer. 2021 Feb;21(1):e120-e127. doi: 10.1016/j.clbc.2020.07.007. Epub 2020 Jul 20. Clin Breast Cancer. 2021. PMID: 32778512 Review.
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G, Carbognin L, Arcanà C, Parola S, Ventriglia A, Doronzo A, Garutti M, Orlandi A, Palazzo A, Fabi A, Bria E, Tortora G, Arpino G, Giuliano M, Del Mastro L, De Laurentiis M, Puglisi F. Garufi G, et al. Among authors: carbognin l. Cancer Treat Rev. 2022 Nov;110:102454. doi: 10.1016/j.ctrv.2022.102454. Epub 2022 Aug 11. Cancer Treat Rev. 2022. PMID: 35987149 Review.
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Pellegrino B, Tommasi C, Serra O, Gori S, Cretella E, Ambroggi M, Frassoldati A, Bisagni G, Casarini C, Bria E, Carbognin L, Fiorio E, Mura A, Zamagni C, Gianni L, Zambelli A, Montemurro F, Tognetto M, Todeschini R, Missale G, Campanini N, Silini EM, Maglietta G, Musolino A. Pellegrino B, et al. Among authors: carbognin l. J Immunother Cancer. 2023 Nov 28;11(11):e007667. doi: 10.1136/jitc-2023-007667. J Immunother Cancer. 2023. PMID: 38016718 Free PMC article. Clinical Trial.
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories.
Sposito M, Belluomini L, Pontolillo L, Tregnago D, Trestini I, Insolda J, Avancini A, Milella M, Bria E, Carbognin L, Pilotto S. Sposito M, et al. Among authors: carbognin l. J Pers Med. 2023 Sep 22;13(10):1427. doi: 10.3390/jpm13101427. J Pers Med. 2023. PMID: 37888038 Free PMC article. Review.
Muscle derangement and alteration of the nutritional machinery in NSCLC.
Trestini I, Gkountakos A, Carbognin L, Avancini A, Lanza M, Molfino A, Friso S, Corbo V, Tortora G, Scarpa A, Milella M, Bria E, Pilotto S. Trestini I, et al. Among authors: carbognin l. Crit Rev Oncol Hematol. 2019 Sep;141:43-53. doi: 10.1016/j.critrevonc.2019.06.007. Epub 2019 Jun 15. Crit Rev Oncol Hematol. 2019. PMID: 31228648 Review.
The obesity paradox in cancer: clinical insights and perspectives.
Trestini I, Carbognin L, Bonaiuto C, Tortora G, Bria E. Trestini I, et al. Among authors: carbognin l. Eat Weight Disord. 2018 Apr;23(2):185-193. doi: 10.1007/s40519-018-0489-y. Epub 2018 Feb 28. Eat Weight Disord. 2018. PMID: 29492860 Review.
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I, Conciatori F, Bazzichetto C, Bria E, Carbognin L, Malaguti P, Ferretti G, Cognetti F, Milella M, Ciuffreda L. Falcone I, et al. Among authors: carbognin l. Int J Mol Sci. 2020 Nov 10;21(22):8419. doi: 10.3390/ijms21228419. Int J Mol Sci. 2020. PMID: 33182542 Free PMC article. Review.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: carbognin l. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A. Duranti S, et al. Among authors: carbognin l. Cancers (Basel). 2021 Oct 16;13(20):5198. doi: 10.3390/cancers13205198. Cancers (Basel). 2021. PMID: 34680350 Free PMC article. Review.
71 results